Author's Accepted Manuscript

Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know

Steven R. Feldman, Jerry Bagel, Shahla Namak



PII: S0002-9629(17)30695-X

DOI: https://doi.org/10.1016/j.amjms.2017.12.014

Reference: AMJMS592

To appear in: The American Journal of the Medical Sciences

Received date: 27 July 2017 Revised date: 21 December 2017 Accepted date: 25 December 2017

Cite this article as: Steven R. Feldman, Jerry Bagel and Shahla Namak, Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know, *The American Journal of the Medical Sciences*, doi:10.1016/j.amjms.2017.12.014

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CCEPTED MANUSCRIPT

Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing

Physician Needs to Know

Steven R. Feldman, MD^a Jerry Bagel, MD^b Shahla Namak, MD^a

^aWake Forest University School of Medicine, Department of Dermatology, Wake Forest

University School of Medicine, 4618 Country Club Road, Winston-Salem, NC, 27104,

E-mails: sfeldman@wakehealth.edu, snamak@wakehealth.edu

^bWindsor Dermatology/Psoriasis Treatment Center of Central New Jersey (PTCCNJ),

59 One Mile Road Extension, East Windsor, NJ, 08520

E-mail: Dreamacres1@aol.com

Address correspondence and reprint requests to:

Shahla Namak, Wake Forest University School of Medicine, Department of Dermatology,

Wake Forest University School of Medicine, 4618 Country Club Road, Winston-Salem, NC,

27104

Email: snamak@wakehealth.edu

Source of Funding Statement: None

Phone: 336-716-4479

Short Title: Biosimilars in immune-mediated conditions for Practicing Physicians

Key Indexing Terms: Biologic; Biosimilar; Immunology; Rheumatology

Conflicts of Interest

Dr. Feldman reports personal fees from Merck, Sandoz, and Boehringer Ingelheim; grants

and personal fees from Novartis, Lilly, Janssen, and AbbVie outside the submitted work.

Dr Bagel has served as speaker, investigator and consultant for Leo, Celgene, AbbVie,

Janssen, Eli-Lilly; was an investigator for Novartis; and served as a consultant for Amgen.

Dr Namak has nothing to disclose.

1

Download English Version:

https://daneshyari.com/en/article/8651749

Download Persian Version:

https://daneshyari.com/article/8651749

<u>Daneshyari.com</u>